Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells

Abstract

Background

Worldwide, oral squamous cell carcinoma (potentially mediated by HER2) is recognized as the most commonly occurring malignant neoplasm of the oral cavity. Anti-HER2 nanobodies conjugated to gold-silica nanoshells and used as photothermal treatment for oral squamous cell carcinoma may provide a novel therapeutic alternative to current treatment for this disease.

Methods

KB epithelial or HeLaS3 cell cultures (controls) were exposed to these immunonanoshells, and plasmon resonance electron initiation specific to gold was employed to burn the tumor cells.

Results

Following this treatment, significant cell death occurred in the KB tumor cell cultures while there was no evidence of cellular damage or death in the HeLaS3 cell cultures.

Conclusion

These findings suggest that photothermal treatment of oral squamous cell carcinoma has considerable advantages.

Keywords:

• anti-HER2 immunonanoshells
• gold-silica nanoshells
• photothermal treatment
• oral squamous cell carcinoma

Introduction

Oral squamous cell carcinoma is histopathologically characterized by invasive islands of malignant squamous epithelial cells, and accounts for more than 90% of all malignant neoplasms of the oral cavity. The majority of these cancers are located on the tongue, mainly at the lateral posterior border.^1,2 Current treatments are based on the clinical stage of the disease and may include surgical excision, radiation therapy, chemotherapy, or combination therapy, as well as new investigational methods such as immunotherapy or gene therapy.^1,3,4 Surgical excision can result in complications, and the use of conventional radiotherapy may cause an oral cavity disorder, resulting in reduced patient survival time.⁵ Because local carcinoma recurrences are common and current treatments can result in significant problems, alternative therapeutic approaches are warranted.⁶

Thermal therapy is emerging as a promising alternative strategy that is simple to perform and is advantageous as an alternative treatment for certain malignancies. The use of hyperthermia in the treatment of a variety of solid tumors has been under investigation for quite some time.^7–13

When generating nanoshells, it is possible to manipulate the size and layer of their composition and to conjugate antibodies with the nanoshells to target cancerous cells specifically.^14–16 The nanoshells neither absorb nor scatter light emission, thereby allowing local destruction of tumor tissue.^14,17,18 It is also possible to construct gold nanoshells that preferentially absorb light in the near infrared region of the spectrum (700–1100 nm) so that optical transmission through tissue is optimal.¹⁹ This property could be used for noninvasive excitation of nanoshells within tissue. Using antibody conjugation to target nanoparticle-encapsulated drugs to tumor sites has increasingly been incorporated as a therapeutic approach in cancer.²⁰ A relatively high incidence of endothelial growth factor receptor and HER2 overexpression has been reported in oral squamous cell carcinoma.^21–23

A previous study demonstrated that nanoshells injected into mice could accumulate at tumor sites because of the small size of the nanoparticles and enhanced permeability and retention effects.²⁴ Following near-infrared laser irradiation to introduce cellular hyperthermia, tumors were completely eliminated. Neutron activation analysis has been used to detect and qualify gold (nanoshells) in blood, bone, and other tissues, and has been used to determine nanoshell concentrations in tumors.²⁵ Further, the nanoshell is composed of substances (silica, gold, and targeting antibodies) that have also been used previously as nontoxic pharmacological agents. In this study, for the first time, the efficacy of photothermal treatment/near-infrared laser light with anti-HER2 nanobody-conjugated nanoshells was investigated in an in vitro model of oral squamous cell carcinoma.

Materials and methods

Cell lines and cell culture

All cell lines were obtained from the cell bank at the Pasteur Institute of Iran. HER2-positive KB cells were grown in RPMI 1640 medium (Gibco-Invitrogen Corporation, Auckland, New Zealand). HER2-negative HeLaS3 cells were grown in HAM F12 medium (Gibco-Invitrogen Corporation). All media were supplemented with 10% fetal bovine serum and 1% antibiotics (90 U/mL penicillin and 0.9 μg/mL streptomycin). The cell cultures were maintained at 37°C in a humidified incubator under 5% CO₂.

Gold-silica nanoshell fabrication

The nanoshells were fabricated as previously described.^26,27 All chemicals were purchased from Merck, Hohenbrunn, Germany. Three milliliters of 30% ammonia solution was mixed with 50 mL of absolute ethanol. After this, 1.5 mL of tetraethyl orthosilicate 6.7 mM was added, and the solution was stirred overnight. The silica nanoparticles produced during this process were 100 nm in diameter. Treatment with organosilane produced surface-containing terminal amine groups. To make the nanoparticles functional, we mixed 50 μL of 0.28 mM organosilane with the silica nanoparticles. Following an overnight reaction, the solution was kept at a low boil for one hour to facilitate covalent bonding of organosilane to the surface of the silica nanoparticles. We then added dry ethanol gradually to maintain a constant volume. The solution was centrifuged at 2000 rpm per minute at 4°C for 30 minutes and redispersed in ethanol at least five times to remove excess materials.

For preparation of the gold nanoparticles, we rapidly mixed 45 mL of high-pressure liquid chromatography grade water with 0.5 mL NaOH, 1 mL tetrakis (hydroxymethyl) phosphonium chloride and 1.5 mL HAuCL₄ into a 1% H₂O solution with vigorous stirring. The gold nanoparticles produced were approximately 3 nm in diameter, and were prepared as previously described by Duff et al and stored for two weeks at 6°C.²⁸ Following a 2-week incubation, 25 mg of K₂CO₃ dissolved in 100 mL water was added, and 1.5 mL of 1% 2-chloroauric acid was then vigorously mixed into the solution. Four milliliters of this solution was mixed with 100 mL of silica-gold nanoparticles. Finally, 10 μL of 0.36 mM formaldehyde was added, turning the solution dark blue. This solution was then centrifuged at 2000 rpm per minute at 4°C for 30 minutes and redispersed in high-pressure liquid chromatography grade water at least twice to remove excess materials. The final estimation of the nanoshells was determined by optical absorption profiling using an ultraviolet-visible spectrophotometer (3100; Shimadzu, Tokyo, Japan). The dimensions of the nanoshells were assessed by electron microscopy (EM-900, 800 Kev; Zeiss, Oberkochen, Germany). The nanoshells used in this study were approximately 100 nm in diameter with a 10 nm thick gold shell and displayed an extinction peak at 820 nm.

Nanoshells anti-HER2 nanobody conjugation

Approximately 8 × 10⁸ nanoshells were suspended in a K₂CO₃ solution (0.2 M, pH 8.2–8.8) at a final concentration of 8 μg/mL of SR-86 nanobody and then stirred gently using a stirrer magnet bar at room temperature. Next, 20 μL of 1% polyethylene glycol (molecular weight 20,000) was added per mL of solution and stirred gently for 5 minutes at room temperature. A 20 μL sample of 10% bovine serum albumin solution in phosphate-buffered saline (pH 7.2–7.4) was added for each milliliter of suspension and gently stirred for 5 minutes. The solution was poured into a tube (Sigma 3K30 Laborzentrifugen, Germany) and centrifuged at 14,000 g for 45 minutes at 4°C to remove excess reagents, such as unbound nanoshells or nanobodies. Following centrifugation, we removed 4.5 mL of supernatant and resolved the pellet in 20 μL of 1% bovine serum albumin in phosphate-buffered saline (pH 7.2–7.4) per mL of solution with gentle stirring for 5 minutes. The solution was then centrifuged at 14,000 g for 45 minutes at 4°C. This step was then repeated, with the centrifugation step reduced to 30 minutes. The pellet was resuspended in 1% bovine serum albumin and stored at 4°C.

Molecular imaging of HER2 expression and in vitro photothermal therapy

Cells were seeded onto 96-well plates at a density of 5 × 10³ cells/cm² and grown until nearly confluent. Images were taken with a Zeiss fluorescence microscope before and after laser irradiation. Cells were washed with phosphate-buffered saline twice, and 8 × 10⁸ nanoshells/mL were mixed with cell culture media without fetal bovine serum at an 8:1 ratio. The culture medium was removed from each well, and replaced with 100 μL of the nanoshell solution. After one hour of incubation at 37°C under 5% CO₂, the cells were washed three times with phosphate-buffered saline to remove the unbound nanoshells. Next, a 4 mm diameter spot in each well was exposed to laser light (Med Art, Hvidovre, Denmark) at 820 nm and 4 W/cm² for two minutes. Eight hours later, the cells were examined using the MTT assay.²⁹ A 50 μL sample of MTT dye (Merck, 10 mg/mL in phosphatebuffered saline) was added to each well. The plates were incubated at 37°C for three hours and then centrifuged at 800 g for 10 minutes. Finally, the supernatant was aspirated. Formazan production was determined one hour after addition of 100 μL of dimethyl sulfoxide (Merck) using an enzyme-linked immunosorbent assay microplate reader (Labsystem, Multiskan MS, England) at 575 nm.

Results

Production of gold-silica nanoshells

The gold-silica nanoshells were produced as previously described, and aliquots were conjugated to a targeting antibody. The extra sites on the nanoshells were blocked by adding a solution of bovine serum albumin. Figure 1 indicates that the absorption spectra of the bare nanoshells were nearly identical. The antibody did not have any detectable adsorption in the near-infrared region, indicating that the optical properties of the nanoshells must originate from the bare nanoshells. This finding suggests that the properties of the nanoshells were not altered by antibody conjugation or addition of bovine serum albumin. We visualized the gold-silica nanoshells using transmission electron microscopy (Figure 2).

Figure 1 Spectral characteristics of near-infrared-absorbing nanoshells. The absorption spectrum shows the absorbing near-infrared nature (820 nm) of nanoshells with dimensions consisting of a silica core of 100 nm in diameter and shells approximately 10 nm thick. Predicted optical properties were confirmed using ultraviolet-visible spectrophotometry.

Figure 2 Transmission electron microscopic image of gold-silica nanoshells with an overall diameter of 111 ± 3 nm.

Note: Scale bar = 100 nm.

HER2-targeted nanoshells in KB and HeLaS3 cell lines

As expected, bare nanoshells could be absorbed nonspecifically to the cell surface in both cell lines. Nonspecific attachment of the bare nanoshells could induce cell death in the area treated with laser, but cell mortality was low in the KB and HeLaS3 cells.

HER2-targeted nanobody-conjugated nanoshells in KB and HeLaS3 cells

The nanoshells conjugated to nanobodies were able to induce cell death effectively in KB cells overexpressing HER2 on their surface. The specificity and affinity of binding was confirmed previously by antibodies and antigen-based studies.²² A comparison of the images demonstrated the relationship between nanoshell absorption and cell cytotoxicity following laser treatment (Figure 3A and B versus Figure 4A and B).

Figure 3 (A) HER2-positive KB cells exposed to anti-HER2 immunonanoshells (nanobody-conjugated nanoshells). (B) Cytotoxicity was observed in cells treated with near-infrared laser. Images represent cells targeted with anti-HER2 nanoshells only.

Figure 4 (A) HER2-negative HeLaS3 cells treated with anti-HER2 immunonanoshells. (B) No cytotoxicity was observed in HeLaS3 cells following near-infrared laser treatment.

Viability staining

A cell viability staining experiment²⁹ was performed in all the experimental groups. These assays were used to evaluate the number of living cells following near-infrared radiation. Each cell line was divided in four groups, and the viability of each group of cells was evaluated by the MTT assay (Figures 5–8). Nonspecific binding was responsible for 0.6%–1.5% of cell death in KB cells while this number was slightly lower at 0.3%–0.9% in HeLaS3 cells (Figures 6 and 7). The highest mortality was observed in KB cells (69.4%) following addition of the nanobody-nanoshell conjugates and subsequent exposure to laser radiation. Mortality was much lower in the HeLaS3 cells, at approximately 4% (Figure 8). It should be noted that there was loss of both viable and dead cells due to reagent removal and washing during the experiment. It should be noted that there was a significant difference between all experimental groups.

Figure 5 MTT assay results for normal HER2-positive (KB) and HER2-negative (HeLaS3) cells before and after near-infrared laser irradiation.

Abbreviation: NIR, near-infrared.

Figure 6 MTT assay results for KB and HeLaS3 cells following treatment with HER2-targeted nanobodies and near-infrared laser.

Abbreviation: NIR, near-infrared.

Figure 7 MTT assay results for KB and HeLaS3 cells exposed to bare nanoshells. Both cell types were treated with a near-infrared laser.

Abbreviation: NIR, near-infrared.

Figure 8 Anti-HER2 immunonanoshells (nanobody-conjugated nanoshells) were added to KB and HeLaS3 cells, and the cells were treated with an near-infrared laser. An MTT assay was performed on both cell types and our results indicated that immunotargeted nanoshells can selectively induce specific cell death in vitro.

Abbreviation: NIR, near-infrared.

Discussion

Improved therapies for oral squamous cell carcinoma, including surgery, chemotherapy, radiotherapy, and immunotherapy, are currently being evaluated to determine their efficacy in promoting long-term, disease-free survival. Photothermal therapy is a novel noninvasive treatment approach and is rapidly being recognized as one of the most effective therapeutic strategies for targeting tumor cells specifically.

In this study, anti-HER2 nanobody-tagged gold-silica nanoshells were generated, and their photothermal potency was examined in KB and HeLaS3 cells. Our data demonstrated selective tumor destruction of more than 69.4% of KB (HER2-positive) cells with no mortality in HeLaS3 (HER2-negative) cells. It should be noted that nonspecific binding of conjugated nanoshells and extra reagents was minimized by washing to prevent cell death following near-infrared laser radiation.

Our current data highlight several advantages of nanobody-conjugated nanoshells compared with current treatments for oral squamous cell carcinoma. Nanobody labeling of nanoshells serves to increase nanoparticle specificity and therapeutic efficiency in vitro and is rapidly emerging as a new therapeutic class of immunonanoshells. For use in vivo, increasing nanoparticle specificity would be beneficial in that it would result in a higher accumulation of nanoparticles in the target tissue. It should be noted that there is no resistance to photothermal application for use in vivo. It has been observed that current tumor therapies can induce cancer cells to alter their cell surface marker expression; however, nanoparticles could localize to target cancer cells without causing any detectable cellular alterations. Furthermore, our toxicology results indicate that the anticancer effects of our immunonanoconjugate are limited to the areas exposed to near-infrared laser irradiation. The requirement for the presence of both nanoshells and laser light to induce cell death is promising for use in tumors in which local recurrence is often the most serious risk and the surrounding normal tissues perform critical functions. In conclusion, we demonstrate for the first time that immunonanoshells containing nanobody conjugates can be used to induce selective cancer cell death in vitro. In vivo studies are currently underway in mouse models of oral squamous cell carcinoma to determine the therapeutic efficacy of gold–silica nanobody immunonanoshells.

Acknowledgment

We thank the staff of the Biotechnology Department of Medical Sciences, Tarbiat Modares University, for their technical assistance with this research.

Disclosure

The authors report no conflicts of interest in this work.